title: Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.
abstract: Over-expression of the HER2/neu receptor occurs in 20 to 30 percent of breast tumors and is linked to poorer prognosis. The HER2/neu expression status determines whether or not patient will receive trastuzumab-based treatment. In clinical practice, over-expression of HER2/neu is routinely identified using Immunohistochemistry (IHC) or Fluorescence in Situ Hybridization (FISH), both of which are invasive approaches requiring tissue samples. Serum assays for the Extra Cellular Domain of HER2/neu receptor (HER2 ECD) have been reported but the use is very limited due to serum interference factors (e.g. human anti-animal immunoglobulin antibodies) that lead to false test results and inconsistency with tissue Her2 status. We have developed an ELISA based approach using an MBB buffer to eliminate false results and to obtain more accurate assessment of HER2 ECD levels. Using this refined assay we retroactively measured HER2/neu levels from breast cancer patients and controls. Abnormal HER2 ECD levels were detected in about 32% of invasive breast cancer patients but not in controls or patients with benign diseases. In addition, we also showed that patients with elevated serum HER2 levels appeared to have worse survival regardless of treatments. In a small group of 12 Ductal Carcinoma in situ (DCIS) patients who received HER2/neu peptide vaccination and surgery, only one patient showed constantly rising HER2 levels after treatment and this patient had recurrence of HER2 positive tumor within 5 years. Our studies indicate that once the serum interference issue is resolved, serum HER2 ECD can have potential clinical utility to supplement the tissue based tests.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, U.S.A.
authors.forename: Lian
authors.initials: L
authors.lastname: Lam
authors.affiliation: Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Czerniecki
authors.affiliation: Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Fitzpatrick
authors.affiliation: Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
authors.forename: Shuwen
authors.initials: S
authors.lastname: Xu
authors.affiliation: Division of Hematology-Oncology, HUP, 16 Penn Tower, Philadelphia, U.S.A.
authors.forename: Lynn
authors.initials: L
authors.lastname: Schuchter
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, U.S.A.
authors.forename: Xiaowei
authors.initials: X
authors.lastname: Xu
authors.affiliation: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, U.S.A.
authors.forename: Hongtao
authors.initials: H
authors.lastname: Zhang
keywords: DCIS; HAIA; HAMA; HER2/neu; Survival; Vaccination
references.citation: Biochim Biophys Acta. 2012 Aug;1826(1):199-208
references.pmid: 22521738
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Oncogene. 2001 Apr 19;20(17):2101-11
references.pmid: 11360194
references.citation: Breast Cancer Res Treat. 1996;40(3):251-5
references.pmid: 8883967
references.citation: Proc Natl Acad Sci U S A. 2001 May 8;98(10):5497-502
references.pmid: 11320219
references.citation: Clin Chem. 2003 Oct;49(10):1579-98
references.pmid: 14500583
references.citation: Nat Rev Clin Oncol. 2011 May;8(5):307-11
references.pmid: 21151204
references.citation: Cancer Res. 2013 Apr 15;73(8):2619-27
references.pmid: 23396586
references.citation: J Immunoassay. 1992;13(2):289-96
references.pmid: 1430244
references.citation: Cancer Res. 1998 Nov 15;58(22):5123-9
references.pmid: 9823322
references.citation: Cancer. 2007 Sep 1;110(5):973-9
references.pmid: 17647245
references.citation: Cancer Res. 2007 Feb 15;67(4):1842-52
references.pmid: 17293384
references.citation: Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):63-6
references.pmid: 7906981
references.citation: Nat Med. 2006 Apr;12(4):473-7
references.pmid: 16532003
references.citation: Breast Cancer Res Treat. 2012 Jun;133(2):799-804
references.pmid: 22418702
references.citation: Cancer Treat Rev. 2012 Apr;38(2):133-42
references.pmid: 21549508
references.citation: Cancer Biol Ther. 2006 Jun;5(6):657-64
references.pmid: 16627989
references.citation: Breast Cancer Res. 2007;9(6):R75
references.pmid: 17976236
references.citation: Cancer. 2012 Sep 1;118(17):4354-62
references.pmid: 22252842
references.citation: Clin Cancer Res. 2011 Apr 1;17(7):2055-64
references.pmid: 21307144
references.citation: Oncogene. 2008 Jun 19;27(27):3870-4
references.pmid: 18264138
references.citation: Int J Mol Sci. 2011;12(3):1505-18
references.pmid: 21673904
references.citation: Tumori. 2006 Jul-Aug;92(4):311-7
references.pmid: 17036522
references.citation: J Clin Invest. 2007 Aug;117(8):2051-8
references.pmid: 17671639
references.citation: Cancer Res. 2011 Mar 1;71(5):1515-9
references.pmid: 21343397
references.citation: Mol Cell Biol. 1993 Apr;13(4):2247-57
references.pmid: 8096058
references.citation: Oncogene. 1987;1(4):423-30
references.pmid: 3330785